| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 |
| 26 Oct 2026 |
8-K: Other Events
On October 26, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the U.S. Food and Drug Administration’s (“FDA’s”) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and re... |
| 23 Oct 2026 |
8-K: Other Events
On October 23, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced that BDR Pharmaceuticals International Pvt. Ltd. (“BDR”) has filed suit against the U.S. Food and Drug Administration (“FDA”) and related Federal D... |
| 29 Sep 2026 |
8-K: Other Events
On September 29, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigationa... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 |
| 23 Jun 2026 |
8-K: Other Events
On June 23, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment fo... |
| 21 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 19, 2026, Phathom Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders voted on the matters disclosed in the Company’s definitive Proxy Stat... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
$58.3 million in Q1 net revenues, a 104% increase year-over-year |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Over 1.1 million total VOQUEZNA® prescriptions filled to date |
| 08 Jan 2026 |
8-K: Other Events
As representatives of the several Underwriters named in Schedule I hereto, |
| 07 Jan 2026 |
8-K: Results of Operations and Financial Condition
FLORHAM PARK, N.J., January 7, 2026 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain prelim... |
| 04 Nov 2025 |
8-K: Other Events
On November 4, 2025, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational trea... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter |
| 27 Oct 2025 |
8-K: Other Events
On October 25, 2025, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-... |
| 06 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings report |
| 16 Jun 2025 |
8-K: Other Events
On June 16, 2025, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”), announced that the U.S. Food and Drug Administration (“FDA”) has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”... |
| 09 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2025, Phathom Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders voted on the matters disclosed in the Company’s definitive Proxy Stat... |
| 06 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
This letter responds to your citizen petition submitted on behalf of Phathom Pharmaceuticals, Inc. (Phathom), and received on December 11, 2024 (Petition). In the Petition, you request that the Food and Drug Administration (FDA or Agency... |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers |
Loading...